Soichiro Morinaga1, Yoshiyasu Nakamura2, Yohei Atsumi3, Masaaki Murakawa3, Koichiro Yamaoku3, Toru Aoyama3, Satoshi Kobayashi4, Makoto Ueno4, Manabu Morimoto4, Tomoyuki Yokose5, Yohei Miyagi2. 1. Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Asahiku, Yokohama, Japan morinagas@kcch.jp. 2. Department of Molecular Pathology, Kanagawa Cancer Center, Asahiku, Yokohama, Japan. 3. Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Asahiku, Yokohama, Japan. 4. Department of Gastrointestinal Medicine, Kanagawa Cancer Center, Asahiku, Yokohama, Japan. 5. Department of Pathology, Kanagawa Cancer Center, Asahiku, Yokohama, Japan.
Abstract
BACKGROUND: The overexpression of microRNA-21 (miR-21) in pancreatic cancer has been implicated in drug resistance to gemcitabine. Thus far, miR-21 has gained wide attention as a potential biomarker to predict the clinical response in patients with pancreatic cancer receiving gemcitabine. The aim of this study was to evaluate the predictive value of miR-21 expression, determined by locked nucleic acid in situ hybridization (LNA-ISH), in patients with pancreatic cancer who underwent adjuvant gemcitabine after curative surgery. MATERIALS AND METHODS: Tumor miR-21 expression was analyzed via LNA-ISH and correlated with the clinical outcomes of the patients treated with adjuvant gemcitabine. RESULTS: The overexpression of miR-21 in pancreatic cancer, determined by LNA-ISH, was significantly and independently associated with a shorter disease-free survival in patients who received adjuvant gemcitabine after curative resection. CONCLUSION: The LNA-ISH analysis of miR-21 may serve as a significant predictor for gemcitabine resistance in patients with pancreatic cancer undergoing adjuvant gemcitabine after curative resection. Copyright
BACKGROUND: The overexpression of microRNA-21 (miR-21) in pancreatic cancer has been implicated in drug resistance to gemcitabine. Thus far, miR-21 has gained wide attention as a potential biomarker to predict the clinical response in patients with pancreatic cancer receiving gemcitabine. The aim of this study was to evaluate the predictive value of miR-21 expression, determined by locked nucleic acid in situ hybridization (LNA-ISH), in patients with pancreatic cancer who underwent adjuvant gemcitabine after curative surgery. MATERIALS AND METHODS: Tumor miR-21 expression was analyzed via LNA-ISH and correlated with the clinical outcomes of the patients treated with adjuvant gemcitabine. RESULTS: The overexpression of miR-21 in pancreatic cancer, determined by LNA-ISH, was significantly and independently associated with a shorter disease-free survival in patients who received adjuvant gemcitabine after curative resection. CONCLUSION: The LNA-ISH analysis of miR-21 may serve as a significant predictor for gemcitabine resistance in patients with pancreatic cancer undergoing adjuvant gemcitabine after curative resection. Copyright
Authors: Petr Karasek; Natalia Gablo; Jan Hlavsa; Igor Kiss; Petra Vychytilova-Faltejskova; Marketa Hermanova; Zdenek Kala; Ondrej Slaby; Vladimir Prochazka Journal: Cancer Genomics Proteomics Date: 2018 Jul-Aug Impact factor: 4.069